ANG1005 in Leptomeningeal Disease From Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a
Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed
leptomeningeal disease and previously treated brain metastases.